By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, e-commerce, Drug Stores and Others) & Region for 2024 to ...

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of combined findings from a social media ...

Research and development activities, coupled with a rising demand for effective narcolepsy treatments, are additional factors fueling market expansion. However, challenges such as low per capita ...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

AXS-12 is an investigational highly selective potent norepinephrine reuptake inhibitor and cortical dopamine modulator.

A collection of common and new medications is showing good results against the constellation of symptoms that individualize ...

potentially offering new treatments for narcolepsy and neurological disorders. This development could position NLS as a significant player in the biopharmaceutical market, with plans to expand ...

(MENAFN- GlobeNewsWire - Nasdaq) Narcolepsy treatment market by Product (Narcolepsy Treatment Drugs and Devices), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, e-commerce ...

NLS Pharmaceutics (NLSP) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now ...

AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) ...

Axsome's AXS-12 reduces narcolepsy symptoms, positioning the company for success. Find out why AXSM stock is a buy with ...